Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.

被引：0
作者：
Yabe, Michitoshi
Kenmotsu, Hirotsugu
Kodama, Hiroaki
Nishioka, Naoya
Miyawaki, Eriko
Miyawaki, Taichi
Mamesaya, Nobuaki
Kobayashi, Haruki
Omori, Shota
Wakuda, Kazushige
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Takahashi, Toshiaki
机构：
[1] Shizuoka Canc Ctr, Sunto Gun, Japan
[2] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[3] Shizuoka Canc Ctr, Shizuoka, Japan
[4] Shizuoka Canc Ctr, Div Thorac Oncol, Sunto Gun, Shizuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21113
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [22] Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort
    Bedas, Aseel
    Peledc, Nir
    Rabinovich, Natalie Maimon
    Mishaeli, Moshe
    Shochat, Tzippy
    Zer, Alona
    Rotem, Ofer
    Allen, Aaron M.
    Bar, Jair
    Dudnik, Elizabeth
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (05) : 275 - 282
  • [23] Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1311 - E1316
  • [24] A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ)
    Scagliotti, Giorgio
    Kim, Dong-Wan
    Shaw, Alice Tsang
    Ou, Sai-Hong Ignatius
    Riely, Gregory J.
    Gettinger, Scott N.
    Besse, Benjamin
    Thomas, Michael
    Salgia, Ravi
    Wilner, Keith D.
    Bartlett, Cynthia Huang
    Polli, Anna
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer
    Zheng, Bei
    Jiang, Hong
    Yang, Wenjuan
    Li, Ying
    Liang, Bingqing
    Zhu, Jun
    Chen, Nanmei
    Chen, Miao
    Zhang, Meiling
    CANCER MEDICINE, 2023, 12 (15): : 15983 - 15997
  • [26] Clinical benefit from pemetrexed before and after crizotinib exposure in patients with ALK positive non-small cell lung cancer (ALK plus NSCLC).
    Berge, Eamon
    Delee, Maxon
    Lu, Xian
    Baron, Anna E.
    Solomon, Benjamin J.
    Doebele, Robert Charles
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy
    Song, Zhengbo
    Zhang, Yiping
    Yu, Xinmin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S238 - S238
  • [28] ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
    Guerin, Annie
    Sasane, Medha
    Zhang, Jie
    Macalalad, Alexander R.
    Galebach, Philip
    Jarvis, John
    Kageleiry, Andrew
    Culver, Kenneth
    Wu, Eric Q.
    Wakelee, Heather
    CANCER EPIDEMIOLOGY, 2015, 39 (03) : 307 - 312
  • [29] A LARGE RETROSPECTIVE ANALYSIS OF PEMETREXED (PEM) ACTIVITY IN PATIENTS (PTS) WITH ALK-POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) PRIOR TO CRIZOTINIB (CRIZ) TREATMENT
    Scagliotti, G.
    Kim, D. W.
    Shaw, A. T.
    Ou, S. I.
    Riely, G. J.
    Gettinger, S.
    Besse, B.
    Wilner, K.
    Tang, Y.
    Bartlett, C. H.
    ANNALS OF ONCOLOGY, 2012, 23 : 415 - 415
  • [30] Efficacy and safety of lorlatinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study
    Shaw, Alice Tsang
    Ou, Sai-Hong Ignatius
    Felip, Enriqueta
    Bauer, Todd Michael
    Besse, Benjamin
    Gadgeel, Shirish M.
    Camidge, D. Ross
    Lin, Chia-Chi
    Seto, Takashi
    Soo, Ross A.
    Chiari, Rita
    James, Leonard P.
    Clancy, Jill S.
    Martini, Jean-Francois
    Abbattista, Antonello
    Pithavala, Yazdi K.
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345